For the subsequent regulatory experiments on the effects of PGE2 and COX inhibitors we decided to use IFN-γ stimulated cells as baseline controls, because it is the most potent inducer of both CXCR3 chemokines and a prerequisite for the immune-mediated tumor-suppressive effects of COX inhibitors in murine breast cancer models [23]. The gene discussed is CXCR3; the disease is breast cancer.